• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Korea·Healthcare·017180.KS
Share

MYUNGMOON Pharm co.,Ltd Stocks

₩ 1217Last Updated 23.07.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

₩ 30.73M

₩ 1217
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

MYUNGMOON Pharm Co., Ltd. operates as a pharmaceutical enterprise, comprehensively handling the research, development, production, distribution, and commercialization of medicinal products. Its business activities extend across South Korea and into global markets. The company offers an extensive array of prescription drugs, addressing a broad spectrum of medical conditions. This range includes treatments for musculoskeletal issues like osteoarthritis, inflammation, rheumatoid arthritis, and muscle relaxation, alongside anti-infectives (antibiotics and antifungals), respiratory aids, and gastrointestinal therapeutics. Cardiovascular health is targeted with circulation agents, anti-hypertensive drugs, and antidiabetic medications. Furthermore, their specialized pharmacotherapy solutions cover narcotics, anesthetics, central nervous system agents, female hormone products, osteoporosis treatments, urogenital medications, adrenocortical hormones, oncology drugs, dermal fillers, and anti-obesity agents. Beyond prescription items, MYUNGMOON Pharm also supplies a diverse selection of over-the-counter (OTC) remedies. These encompass medications for nausea, genitourinary concerns, gum disease, liver support, parasitic infections, constipation, oral ailments, diarrhea, and general digestive health. The OTC portfolio further includes cold and flu treatments, calcium supplements, nasal sprays, multi-vitamins, eye nutrition products, eye drops, blood circulation enhancers, and topical preparations such as external skin treatments and localized pain relievers. In addition to its pharmaceutical lines, the firm markets health supplements, quasi-pharmaceuticals, and blended juice beverages. Established in 1983, MYUNGMOON Pharm Co., Ltd. maintains its primary corporate office in Seoul, South Korea.

Company Valuation

Slightly undervalued
5/7

Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EB

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

23.07.2026 16:59

Much Ado About Nothing: Does Kazakhstan Need a Factory to Produce Humanoid Robots?

23.07.2026 16:33

Google Was Fined $1 Billion for Discriminating Against Competing Services in the EU

23.07.2026 16:06

The "Golden Age" of Euro-Denominated Stablecoins: How Investors Can Profit from Them

23.07.2026 15:45

Morning in New York: Corporate Earnings in the Spotlight

23.07.2026 15:35

"Bulls Can Confidently Aim for $100 a Barrel": Brent Jumps Above $98

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026